A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
| Autor: | Byoung Chul Cho, Joong Bae Ahn, Jae Kyung Roh, W. J. Roh, Sun Young Rha, Hyun Cheol Chung, Nae Choon Yoo, Hei Cheul Jeung |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Organoplatinum Compounds Colorectal cancer Phases of clinical research Salvage therapy Irinotecan Gastroenterology Metastasis irinotecan-resistant oxaliplatin-resistant Internal medicine Clinical Studies Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Aged Tegafur Salvage Therapy business.industry Liver Neoplasms Combination chemotherapy S-1 Middle Aged medicine.disease Surgery Oxaliplatin Survival Rate colorectal adenocarcinoma Drug Combinations Oxonic Acid Treatment Outcome Oncology Lymphatic Metastasis Camptothecin Female Neoplasm Recurrence Local business Colorectal Neoplasms medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m−2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3% (95% CI, 0.4–28.1), and the disease control rate was 42.9% (95% CI, 23.3–62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m−2 was well tolerated and can be used in designing further combination chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|